Meanwhile, a previous study has also suggested that SMA can integrate with telomeric repeats and could induce erosion or shortening of telomeric repeats, and thus can probably be considered as a potential anti-cancer drug for targeting telomeric repeats (Phatak et al. 2008). This evidence concerns the gene SMN1 and cancer.